Evidence map›Paper›PMID 42801718›Full record

ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026

Targeted-Penetrating Biomimetic Hybrid Transfersomes for Enhanced Transdermal Gene Transfection in Hypertrophic Scar Therapy.

Hui Xing, Ziyi Zhao, Yuhui Yang, Yichen Lin, Yinglin Xuan, Ziyang Wang, Kai Lv, Xiaoxu Zhu, Zhi Zhang, Dong Ma

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Hui XingDepartment of Burn and Plastic Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Ziyi ZhaoState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Yuhui YangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Yichen LinState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Yinglin XuanState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Ziyang WangState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Kai LvState Key Laboratory of Bioactive Molecules and Druggability Assessment, Institute of Biomedical Engineering, Jinan University, Guangzhou, China.
Xiaoxu ZhuDepartment of Burn and Plastic Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Zhi ZhangDepartment of Burn and Plastic Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.
Dong MaDepartment of Burn and Plastic Surgery, Guangzhou Red Cross Hospital, Jinan University, Guangzhou, China.ORCID https://orcid.org/0000-0002-1814-7348

Funding

Excellent Graduate Student Cultivation Program of Jinan University 2026CXB033Guangzhou Municipal Science and Technology Bureau 2025A03J3599Guangzhou Science and Technology Project 2023A03J0523National Natural Science Foundation of China 32171369
6 · The paper itself

Abstract

Hypertrophic scar (HS) is a recurrent and inflammatory dermal fibrotic disorder, characterized by abnormal fibroblast proliferation and excessive extracellular matrix (ECM) deposition. Affecting over 310 million patients worldwide, while effective strategies to halt progression remain lacking. The TGF-β-mediated fibrotic cascade is the central driver of HS, and siRNA-based therapeutics offer a promising gene-level intervention owing to their high sequence specificity and low off-target risk. However, siRNA translation is limited by rapid degradation, poor transfection, insufficient targeting, and the dense scar barrier that restricts noninvasive delivery. Proteomic analysis revealed that hypertrophic scar fibroblasts (HSFs) exhibit enhanced bioadhesion and protein-binding functions, with Thy-1 membrane glycoprotein highly and specifically expressed, providing a target for HSFs-active delivery. We hybridized HSFs membranes with cationic transfersomes using ultrasonic co-extrusion and achieved efficient loading of TGF-β1 siRNA through electrostatic self-assembly. This membrane-hybridized platform enabled multipathway transdermal delivery of siRNA via intercellular transport, transcytosis, and skin appendageal routes, while improving transfection, immune evasion, and homotypic targeting. Studies demonstrated efficient silencing of TGF-β1, suppression of α-SMA, ECM deposition, and pro-inflammatory cytokine release, thereby mitigating fibrotic progression. The system provides an innovative strategy for transdermal targeted siRNA therapy of HS and other skin diseases requiring genetic intervention.

Indexed as

active targetinghybrid transfersomeshypertrophic scarsiRNA therapytransdermal transfection

Identifiers

PMID42801718
PMCPMC13616318

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.